EurekAlert! · Dec 2023
UCLA/Duke-NUS research on RNA splicing and cardiomyocyte maturation included Forcyte Biotechnologies as a collaborating institution, reinforcing the company’s relevance in cardiac mechanobiology research.
Discover drugs that control how much cells "squeeze" to treat disease
Company research
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Overview
Forcyte Biotechnologies is a Los Angeles-based, seed-stage biotechnology company that uses mechanobiology to discover drugs by measuring how cells contract/squeeze rather than relying only on conventional biochemical readouts. Its flagship FLECS platform quantifies single-cell mechanical function in high-throughput 384-well format and underpins both external pharma partnerships and an internal mechano-therapeutic pipeline.
Primary product
FLECS (Force-Linked ECM Cytometry) mechanomics platform
Founded
2017
Headquarters
1100 Glendon Ave Fl 17, Los Angeles, CA 90024, United States
Team size
1-10
Industry
Biotechnology
Sub-industry
Mechanobiology drug discovery / biotechnology research
Offices
Open Positions
0 jobs at Forcyte Biotechnologies
No open positions
Check back later for new openings